Drug Approval | November 30, 2022
AstraZeneca’s Dapagliflozin receives CDSCO approval
Dapagliflozin reduces the risk of sustained eGFR, cardiovascular deaths and hospitalization for heart failure in adults with CKD
Dapagliflozin reduces the risk of sustained eGFR, cardiovascular deaths and hospitalization for heart failure in adults with CKD
The company offers a wide portfolio of services including integrated doctor-led prescription e-commerce enablement, digital health record management, and smart clinics.
Program will fight the rising incidence of antimicrobial (drug) resistance and improve patient outcomes
The show will be a part of the India Pharma Week, a marquee celebration catering to every need of the pharma community attendees
Dr. Mandaviya agreed to host the Stop TB Partnership’s 36th Board meeting on March 25-26, 2023 in Varanasi
Phase III trial also demonstrated a statistically significant reduction (14%) in hospitalization for any cause, bringing potential relief for patients and reducing burden on healthcare systems
Indigenously-developed molecular diagnostics have helped expand the reach of diagnosis to every part of the country today
Approval based on HIMALAYA Phase III trial results which showed single priming dose of Imjudo added to Imfinzi reduced risk of death by 22% vs. sorafenib
High-level results from the MESSINA Phase III trial showed that AstraZeneca's Fasenra (benralizumab) did not meet one of the two dual-primary endpoints.
A MoU was signed between Ministry of Ayush and Ministry of Tribal Affairs to collaborate in Ayush sector
Subscribe To Our Newsletter & Stay Updated
